Testing effectiveness (Phase 2)Looking for participantsNCT06932068
What this trial is testing
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Who this might be right for
HER2 NegativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University 77